Forte Biosciences (FBRX) Net Income Growth (3y) (2019 - 2026)
Forte Biosciences (FBRX) Net Income Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | 9.16% |
| 2 | Nanobiotix | 1,942.19 Bn | 1,942.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 475.46 Bn | 470.67 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 123.19 Bn | 115.94 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.44 Bn | 60.69 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 63.20 Bn | 63.20 Bn | - | - |
| 8 | Argenx Se | 57.08 Bn | 51.90 Bn | 1.41 Bn | 79.26% |
| 9 | Revolution Medicines | 38.11 Bn | 38.11 Bn | - | - |
| 10 | Forte Biosciences | 1.36 Bn | 1.31 Bn | - | -47.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.31% |
| Dec 31, 2025 | -70.07% |
| Sep 30, 2025 | -116.63% |
| Jun 30, 2025 | -96.61% |
| Mar 31, 2025 | -77.11% |
| Dec 31, 2024 | 16.76% |
| Sep 30, 2024 | 0.30% |
| Jun 30, 2024 | 23.70% |
| Mar 31, 2024 | 35.45% |
| Dec 31, 2023 | 14.54% |
| Sep 30, 2023 | 39.15% |
| Jun 30, 2023 | 39.94% |
| Mar 31, 2023 | -36.46% |
| Dec 31, 2022 | 22.09% |
| Sep 30, 2022 | 42.72% |
| Jun 30, 2022 | -51.67% |
| Mar 31, 2022 | 45.16% |
| Dec 31, 2021 | 10.07% |
| Sep 30, 2021 | -183.59% |
| Jun 30, 2021 | -21.59% |